This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Yi-Hsiang Chen, MD, PhD; Margarida C. Magalhaes, MD

Arch Intern Med. 1990;150(3):605-610.

Abstract
• Clinical data of 65 patients with myeloma were analyzed to identify factors associated with hypoalbuminemia. The serum albumin level was not affected by patient age and gender, type of myeloma, and the occurrence of Bence Jones protein, lytic bone lesions, or hypercalcemia, and it was not related to changes in body weight or in liver and renal function. The albumin level, lower in patients with proteinuria, was unrelated to severity of proteinuria. Albumin level correlated significantly with the monoclonal IgG level, hemoglobin concentration, clinical stage of disease, and estimated body tumor burden. Further analysis indicated the disease stage or the tumor burden as the dominant factor in determining albumin level. An albumin level of 29.0 g/L or less identified unequivocally advanced disease. Practically all patients with stage III myeloma had a serum albumin level of 37.0 g/L or less. Thus, hypoalbuminemia is primarily related to the extent of myeloma proliferation and is therefore of diagnostic and prognostic importance.

(Arch Intern Med. 1990;150:605-610)

Author Affiliations
From the Department of Medicine, University of Illinois College of Medicine, and Veterans Administration West Side Medical Center, Chicago. Dr Magalhaes is now with Case Western Reserve University School of Medicine, Cleveland, Ohio.

Footnotes
Accepted for publication August 28,1989.

Reprint requests to Department of Medicine (m/c 787), University of Illinois College of Medicine, PO Box 6998, Chicago, IL 60680 (Dr Chen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dose-dependent Effect of Thalidomide on Overall Survival in Relapsed Multiple Myeloma
Neben et al.
Clin. Cancer Res. 2002;8:3377-3382.
ABSTRACT | FULL TEXT  

High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma
Neben et al.
Clin. Cancer Res. 2001;7:2675-2681.
ABSTRACT | FULL TEXT  

No Serum Albumin in Myeloma
Rubinstein
Arch Intern Med 1991;151:618-618.
ABSTRACT  

No Serum Albumin in Myeloma-Reply
Chen
Arch Intern Med 1991;151:618-619.
ABSTRACT